These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26285658)

  • 1. 2005 Donor Eligibility Requirements: Unintended Consequences for Stem Cell Development.
    Couture LA; Carpenter MK
    Stem Cells Transl Med; 2015 Oct; 4(10):1097-100. PubMed ID: 26285658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisions to Exceptions Applicable to Certain Human Cells, Tissues, and Cellular and Tissue-Based Products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Jun; 81(120):40512-8. PubMed ID: 27373010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling. Interim final rule; opportunity for public comment.
    Food and Drug Administration, HHS
    Fed Regist; 2005 May; 70(100):29949-52. PubMed ID: 15915582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2015 May; 80(99):29841-906. PubMed ID: 26003966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differing standards for the NIH Stem Cell Registry and FDA approval render most federally funded hESC lines unsuitable for clinical use.
    Jonlin EC
    Cell Stem Cell; 2014 Feb; 14(2):139-40. PubMed ID: 24506880
    [No Abstract]   [Full Text] [Related]  

  • 6. MSC-based product characterization for clinical trials: an FDA perspective.
    Mendicino M; Bailey AM; Wonnacott K; Puri RK; Bauer SR
    Cell Stem Cell; 2014 Feb; 14(2):141-5. PubMed ID: 24506881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 May; 69(101):29785-834. PubMed ID: 15160713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The case for regulatory compliance of electronic medical records about human tissue intended for transplantation.
    Carrier R
    J Healthc Inf Manag; 2004; 18(4):61-6. PubMed ID: 15537136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Food and Drug Administration and pragmatic clinical trials of marketed medical products.
    Anderson ML; Griffin J; Goldkind SF; Zeitler EP; Wing L; Al-Khatib SM; Sherman RE
    Clin Trials; 2015 Oct; 12(5):511-9. PubMed ID: 26374684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
    Carpenter MK; Couture LA
    Regen Med; 2010 Jul; 5(4):569-79. PubMed ID: 20632860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic cost for implementation of the U.S. Food and Drug Administration's Code of Federal Regulations Title 21, Part 1271 in an egg donor program.
    Baker VL; Gvakharia MO; Rone HM; Manalad JR; Adamson GD
    Fertil Steril; 2008 Sep; 90(3):537-45. PubMed ID: 17953961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part II--a method of software documentary analysis.
    Ilic N; Savic S; Siegel E; Atkinson K; Tasic L
    Stem Cells Transl Med; 2012 Dec; 1(12):909-20. PubMed ID: 23283552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new era in the ethics of human embryonic stem cell research.
    Lo B; Zettler P; Cedars MI; Gates E; Kriegstein AR; Oberman M; Reijo Pera R; Wagner RM; Wuerth MT; Wolf LE; Yamamoto KR
    Stem Cells; 2005; 23(10):1454-9. PubMed ID: 16293581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data Integrity: History, Issues, and Remediation of Issues.
    Rattan AK
    PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of hematopoietic stem cell processing and transplantation.
    Rowley SD
    Int J Hematol; 2002 Apr; 75(3):237-45. PubMed ID: 11999350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.